MedDataX Logo

Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol

NCT ID: NCT00524290

Last Updated: 2018-06-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-04-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this multinational study are to assess the clinical outcomes of patients with Acinetobacter bloodstream infection and to further assess the predictors of mortality in this patient population. We also aim to characterize the molecular epidemiology of this remarkable organism in an attempt to further understand its transmission dynamics on a global level and to determine whether increased pathogenicity is geographically dependent.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Surveillance Study - Incidence of Antibiotic Resistance in Serial Gram-negative Bloodstream Isolates

NCT00394784

Gram-negative Bacterial Infections
WITHDRAWN

Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase

NCT00414193

Bacteremia AmpC Beta-lactamase
COMPLETED

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

NCT00167999

Gram-Positive Bacterial Infections Escherichia Coli Infections Klebsiella Infections
COMPLETED

Imipenem and Sulbactam in the Treatment of Imipenem-resistant Acinetobacter Baumannii Bacteremia

NCT01374256

Acinetobacter Bacteraemia
UNKNOWN

11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

NCT03424525

Bacterial Infections
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Medical records will be reviewed and information collected to assess the clinical outcomes of patients with Acinetobacter bloodstream infection and to further assess the predictors of mortality in this patient population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acinetobacter Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with Acinetobacter infections

Exclusion Criteria

* Those that do not meet entry criteria
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pittsburgh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yohei Doi

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Paterson, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PRO07080043

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
NCT00177814 COMPLETED
GSK2251052 in Complicated Urinary Tract Infection
NCT01381549 TERMINATED PHASE2
Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases (ESBLs)
NCT00254696 COMPLETED PHASE4
Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance
NCT01788449 COMPLETED
Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs
NCT05224401 RECRUITING PHASE3
Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects
NCT03303924 COMPLETED PHASE1
Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens
NCT04860505 COMPLETED PHASE4
PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
NCT05355350 WITHDRAWN PHASE4
An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia
NCT00502801 COMPLETED PHASE2
Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin
NCT00239161 TERMINATED PHASE4
Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects
NCT04018950 COMPLETED PHASE1
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
NCT03891433 SUSPENDED PHASE4
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
NCT05905055 COMPLETED PHASE3
Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects
NCT02971423 COMPLETED PHASE1
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)
NCT04295551 UNKNOWN NA
Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study
NCT00510614 COMPLETED EARLY_PHASE1
A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy
NCT02045160 UNKNOWN
A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
NCT04505683 COMPLETED PHASE2/PHASE3
Evaluation of Therapeutic Management in ESBL-infected Patients or Carriers by Providing and Sharing a Free Tool - the "ESBL toolKIT"and Interventional Study of a Prospective Cohort of HIV+ Patients Searching for Possible Sexual Transmission Factors in ESBL Carriers
NCT02011009 COMPLETED NA
Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
NCT00195286 COMPLETED
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
NCT05277350 COMPLETED PHASE1
Specialized Proresolving Mediators in Pneumocystis Jirovecii Pneumonia
NCT03606252 COMPLETED NA
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
NCT07326540 NOT_YET_RECRUITING PHASE3
Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
NCT00210990 COMPLETED PHASE3
Tazocin Intervention Study
NCT00478855 COMPLETED PHASE4